Trump nominates Jay Bhattacharya as NIH director

Pharmaceutical

US President-elect Trump has announced another nomination for his healthcare team, now selecting Stanford University professor Dr Jay Bhattacharya as his next director of the National Institutes of Health (NIH), according to a posting on his Truth Social platform yesterday.

Assuming nominations are confirmed Dr Bhattacharya will work closely with Robert F Kennedy Jr, who has been picked to be Secretary of the Health and Human Services department, a particularly contentious choice due to his anti-vaccine activities.

The NIH has a budget of over $47 billion and oversees clinical trials, backs efforts to develop drugs and provides grants to researchers among other functions. Dr Bhattacharya would need to be confirmed by the Senate. Republicans will be in the majority come next year when the Trump administration becomes active.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK